Cure HHT’s Registry Research Selected for Oral Presentation at American Society of Hematology 2025 Annual Meeting
Presentation will raise critical awareness of HHT among hematologists, expanding understanding and earlier recognition of this underdiagnosed genetic disease MONKTON, Md., October 20, 2025 — Cure HHT, the only organization in the world solely dedicated to finding a cure for hereditary hemorrhagic telangiectasia (HHT) and improving the lives of those affected, today announced that…
Cure HHT Leads Global Breakthrough in Bleeding Standards, Paving the Way for Future HHT Therapies
International Consensus Report Published in the American Journal of Hematology Aims to Transform HHT Research, Treatment, and Clinical Trials
A History of Pazopanib
There are no FDA-approved therapeutics for the treatment of HHT. Cure HHT sought to change that. In many ways, the history of pazopanib is not unlike the story of the HHT community. Both are defined by persistence: a long battle for awareness, funding, and ultimately, solutions. Now, after years of dedicated effort, the paths of…
This Landmark HHT Study Could Shift National Attention
We’re excited to share some truly important news for the HHT community. A major new study done in collaboration between Cure HHT, Massachusetts General Hospital, and Diagonal Therapeutics — just published in the American Journal of Hematology — delivers something we’ve never had before: hard data that proves HHT is a serious, high-impact disease that’s…
Volunteers Needed! Join Cure HHT on Capitol Hill
We are calling upon volunteers to Join us in Washington, DC, for HHT Hill Day and be the voice that drives change! Your presence can help make a powerful impact for the HHT community! Our organization exemplifies the Little Engine That Could, and a large part of that success is derived from the community of…
Cure HHT’s 2024 Impact Report
2024: A Year of Significant Transformation and Progress Every year is a different chapter in our story – each bringing us closer to our ultimate goal.. But 2024 was defined by new especially significant and meaningful results in moving science and research forward. This year, thanks to the efforts of our new Therapeutic Development team,…
Press Release: Diagonal Therapeutics to Present Data at ASH 2024 Demonstrating the Economic and Clinical Burden of HHT
Diagonal Therapeutics — who has raised $128 million in Series A funding to support their sole project, a curative HHT therapy — today issued the below press release outlining new research demonstrating the significant healthcare cost impact of HHT. This data will be significantly important in advocating for funding for HHT, as well as attracting…
Press Release: Vaderis Receives FDA Fast Track Designation for Treatment of HHT
The below press release was issued Monday, Nov. 18 by Vaderis Therapeutic, and is substantial news for our community. Cure HHT has worked hand-in-hand with leadership at Vaderis throughout this process — helping encourage them to focus on HHT, informing trial design, and supporting recruitment. We are the catalyst that drives progress for HHT, and this news…
A Monumental $128 Million Step Forward for HHT Research
Today is a monumental day for HHT. The new biotechnology company, Diagonal Therapeutics, officially launched and we wanted to share more about why this is news you simply can’t miss!
In short, Diagonal’s lead program is focused on developing an innovative treatment not just to alleviate the symptoms of HHT – but using antibodies to reverse the formation of vascular malformations altogether. That’s right, there is now a biotechnology company, backed by $128 million in Series A financing, focused entirely on a curative HHT therapy.
For months, Cure HHT has been collaborating with Diagonal’s management team to help make this day a reality. We have connected them to leading HHT scientists to help them further develop their program, and have spent countless hours meeting with venture capital firms to educate them on the burden of this disease and help Diagonal secure funding to launch.